Navigation Links
Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
Date:10/22/2013

SEOUL, South Korea, Oct. 22, 2013 /PRNewswire/ -- Samsung BioLogics today announced that Samsung BioLogics and F. Hoffmann-La Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction. Terms of the agreement will not be disclosed, including financial terms and products to be manufactured.

(Photo: http://photos.prnewswire.com/prnh/20131022/HK01710 )
(Photo: http://www.prnasia.com/sa/2013/10/22/2013102214483444486.html )

"We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Tae-Han Kim, president and CEO of Samsung BioLogics. "This collaboration with the world's largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing."

About Samsung BioLogics

Samsung BioLogics is a full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal antibody & recombinant protein production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product meeting the highest standards of quality and global regulatory compliance. For additional information about the company, please visit http://www.samsungbiologics.com.

Samsung Disclaimer

This press release may contain certain forward-looking statements that reflect our current views and expectations with respect to our performance, businesses, and future events. Please understand that these statements are subject to a number of risks, uncertainties, and assumptions, any of which could cause actual results to materially differ from the plans, objectives, expectations, estimates, and intentions we express. In no event will we or any of our subsidiaries, affiliates, directors, officers, agents, or employees be liable before any third party, including investors, for any investment or business decision made or action taken based on information and statements contained in this press release or for any consequential, special, or similar damages.

Contact:
Samsung BioLogics
Media:
Changsik Park
82-32-455-3710
changsiik.park@samsung.com


'/>"/>
SOURCE Samsung BioLogics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Samsung Thales signs Development Agreement with Novelda
2. iLuv Now Shipping Protective and Stylish Accessories for the Just-Announced Samsung GALAXY Note 8.0
3. iLuv Announces a New Lineup of Cases and Accessories for the New Samsung GALAXY Tab 3
4. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
5. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
6. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Adeona Becomes Synthetic Biologics, Inc.
9. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
10. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
11. CMC Biologics Highlights Technical Acumen at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):